About Us  |  Contact Us  |  Español
VNA of Care New England
VNA of Care New England

New Test Helps Diagnose Intellectual Disability in Children

Scan tracks entire genome from a blood sample
FRIDAY, Jan. 17, 2014 (HealthDay News) -- A new test to help diagnose developmental delays and intellectual disability in children based on genetic abnormalities has been approved by the U.S. Food and Drug Administration.
The Affymetrix CytoScan DX Assay scans the entire genetic code from a blood sample and detects chromosomal variations that can lead to developmental and learning problems in children, the agency said Friday in a news release.
Intellectual disability affects as many as 3 percent of children in the United States, the agency said.
Analysis of 960 blood specimens found the new test was better at detecting chromosomal abnormalities that could lead to intellectual disability than other standard tests, the FDA said.
The new test is produced by Affymetrix Inc., based in Santa Clara, Calif.
More information
Medline Plus has more about intellectual disability (http://www.nlm.nih.gov/medlineplus/ency/article/001523.htm ).
Health Headlines
Blood Test Might Help Prevent Certain Birth DefectsView in a lightbox
Adults Who've Abused Alcohol May Be at Risk for Memory ProblemsView in a lightbox
Annual COPD Costs To Hit $49 Billion by 2020: CDCView in a lightbox
Could a Blood Test Predict Suicide Risk?View in a lightbox
Different Areas of Brain Affected in Autism, Sensory DisordersView in a lightbox
VNA of Care New England
© 2011 Site Index | Disclaimer | Legal Notices